About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Court Report | Main | USPTO Launches Dossier Access »

November 23, 2015

Comments

The issue whether positive evidence of inventive step under section 103 should count in the analysis of an invention under section 101 is one of the questions raised in my amicus brief in Sequemon, citing a range of Supreme Court opinions from the late 1800's e.g Webster Loom v Higgins through the Adams Battery case to KSR. A number of the other briefs in Sequemon raised the same issue. On the whole I think that commercial success may be less compelling than unexpected new technical result. However, the principle is important, and it is to be hoped that it will receive proper and informed consideration when, as hoped, the Sequemon case is taken en banc.

If that happens, it is profoundly to be hoped that the case will be argued by attorneys with sufficient depth of knowledge of patent law and technology. I have recently re-read the oral argument in Myriad, and in hindsight am dismayed by the lack of pertinent knowledge shown by the attorneys on both sides who failed to assist the court by directing attention to pertinent case law and by the somewhat rambling nature of their arguments showed that they were not on top of the case either legally or factually. For example, although bits chopped out of trees were much discussed, the importance of the "manufacture" heading of Section 101 was not clearly pointed out, and the significance of the Hartranft decision approved in Chakrabarty to that discussion did not surface as it should have done. Argument in these cases should be less in the hands of alleged litigation powerhouses and more in the hands of patent professionals who really know the law and have it sat their fingertips so that they can field the awkward questions that the court will routinely throw at them. However, about 15 out of 15 of the attorneys I asked at the recent AIPLA Annual Meeting meeting what were the criteria for a case to go en banc in the Federal Circuit could not give me the answer, which suggests that people of the right caliber may be thin on the ground.

The comments to this entry are closed.

December 2019

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31